Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Noninvasive Probe Characterizes Skin Cancers Morphologically and Biochemically

By LabMedica International staff writers
Posted on 05 Jan 2012
A joint US-Dutch team has developed a noninvasive probe capable of both morphological and biochemical characterization of skin cancers.

The portable instrument combines a Raman spectroscopy (RS) system with an optical coherence tomography (OCT) device and enables the sequential acquisition of coregistered OCT and RS data sets. More...
An Andor (Belfast, Northern Ireland) high-resolution, near-infrared-enhanced Newton camera was chosen as the core element of the Raman diagnosis module.

The probe was developed under the direction of Anita Mahadevan-Jansen from Vanderbilt University (Nashville, TN, USA). It screens large areas of skin up to 15 mm wide to a depth of 2.4 mm with OCT to visualize microstructural irregularities and perform an initial morphological analysis of lesions. The OCT images are then used to identify locations to acquire biochemically specific Raman spectra.

"Having demonstrated the clinical potential of the RS-OCT instrument to rapidly screen at risk patients, we are continuing to develop the dual-modal technique for other applications where noninvasive assessment of both microstructure and biochemical composition are critical to accurate assessment of pathology," said Chetan Patil from Vanderbilt University.

Skin cancer is the most common form of human cancer with annual rates continuing to climb from their current estimate of just over three million new cases each year. Although all skin cancers share the likelihood of a favorable outcome if early diagnosis and complete resection are achieved, diagnosis is invasive, subjective, lengthy, and expensive, involving expert visual inspection, biopsy, and histopathology.

Related Links:
Andor
Vanderbilt University



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.